Do you want to read an article? Please log in or register.
Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease/pneumonitis
Breast Cancer
Related content
CHICAGO 2025
Breast Cancer
T-DXd rechallenge after grade 1 interstitial lung disease appears safe and clinically beneficial in a real-world setting
Further Publications
Antibody-drug conjugate components in association with the incidence of ADC-related interstitial lung disease: A systematic review and meta-analysis
Lung Cancer
Shao T, Yang J, Chen J, Zhang Y, Shou L
doi: 10.1016/j.lungcan.2025.108559
COMMENTED
Breast Cancer
A Pooled Analysis of Trastuzumab Deruxtecan in Patients With HER2-Positive Metastatic Breast Cancer With Brain Metastases
★ 3
Recommended and commented by
Prof. Dr Beat Thürlimann, Faculty Member
Ann Oncol
André F, Cortés J, Curigliano G, Modi S, Li W, Park YH, Chung WP, Kim SB, Yamashita T, Pedrini JL, Im SA, Tseng LM, Harbeck N, Krop I, Nakatani S, Tecson K, Ashfaque S, Egorov A, Hurvitz SA
doi: 10.1016/j.annonc.2024.08.2347
Lung, Respiratory and Thoracic Cancer
Prevalence and prognostic significance of interstitial lung abnormalities in lung cancer: A meta-analysis
Lung Cancer
Yang R, Wang H, Liu D, Li W
doi: 10.1016/j.lungcan.2025.108458
Lung, Respiratory and Thoracic Cancer
Evaluating lung cancer risk factors in adults with interstitial lung disease
Lung Cancer
Dobkin J, Stanifer BP, Salvatore M, Eckhardt CM
doi: 10.1016/j.lungcan.2025.108416
Lung, Respiratory and Thoracic Cancer
Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancer
Oncologist
Skoulidis F, Li BT, Hochmair M, Govindan R, Vincent M, van der Wekken AJ, Reguart Aransay N, O'Byrne KJ, Girard N, Griesinger F, Nishio M, Häfliger S, Lindsay C, Reinmuth N, Paulus A, Papakotoulas P, Kim SW, Ferreira CG, Pasello G, Duruisseaux M, Gennatas S, Dimou A, Mehta B, Kormany W, Nduka C, Sylvester BE, Ardito-Abraham C, Wang Y, de Langen AJ
doi: 10.1093/oncolo/oyae356
Lung, Respiratory and Thoracic Cancer
A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLC
J Thorac Oncol
Ahn MJ, Lisberg A, Goto Y, Sands J, Hong MH, Paz-Ares L, Pons-Tostivint E, Pérol M, Felip E, Sugawara S, Hayashi H, Cho BC, Blumenschein G Jr, Shum E, Lee JS, Heist RS, Cornelissen R, Chang WC, Kowalski D, Zebger-Gong H, Chargualaf M, Gu W, Lan L, Howarth P, Joseph R, Okamoto I
doi: 10.1016/j.jtho.2025.06.002
Multiple Myeloma (MM)
Minimal Residual Disease-Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials
J Clin Oncol
Shi Q, Paiva B, Pederson LD, Dimier N, Talpes E, Prior TJ, Orfao A, Moreau P, Sonneveld P, Kumar SK, Dixon JG, Patel R, Bartlett BJ, Schecter J, McCarthy P, Hose D, Seckinger A, Mattia D, Goldschmidt H, Oliva S, Owen RG, Anderson KC, San-Miguel J, Durie BGM, Munshi N, International Independent Team for Endpoint Approval of Myeloma Minimal Residual Disease (i2TEAMM) Group
doi: 10.1200/JCO-24-02020
Breast Cancer
Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: A systematic review and updated meta-analysis
Cancer Treat Rev
Michelon I, Castro CER, Madeira T, Dacoregio MI, Stecca C, Soares LR, Saeed A, Vilbert M, Cavalcante L
doi: 10.1016/j.ctrv.2025.102882